New major order from China
Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the fourth quarter of approximately SEK 16.5 million.
”This is the second order from Well Lead outside the initial contract and further strengthens that end-customer sales in China are picking up. At the same, we don’t expect to receive any new orders from Well Lead in the beginning of next year, given the high volumes delivered in the third and fourth quarters of this year,” says Christian Kinch, CEO.
In June 2018, Bactiguard signed a combined distribution and license agreement with Well Lead, China's leading manufacturer of consumable medical devices.
The first two product orders, at a combined value of SEK 20 million, were part of the initial contract and delivered in the second and fourth quarters of 2018. A third order, worth SEK 4,8 million was delivered int the third quarter 2019. The fourth order, which has now been received is worth approximately another SEK 16.5 million (EUR 1.6 million).
This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2019-12-27, at 11.45.
For further information, please contact:
Jonas Östregård, SVP Sales & Marketing, mobile: +46 70 521 13 88
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives at www.bactiguard.com